Apremilast

Apremilast

• Product Name Alternative: CC-10004
• CAS Number: 608141-41-9
• UNSPSC Description: Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].
• Target Antigen: Apoptosis; Phosphodiesterase (PDE); TNF Receptor
• Type: Reference compound
• Related Pathways: Apoptosis;Metabolic Enzyme/Protease
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Apremilast.html
• Purity: 99.91
• Solubility: DMSO : 44 mg/mL (ultrasonic)
• Smiles: CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O
• Molecular Weight: 460.50
• References & Citations: [1]Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249.|[2]Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54(8):1336-40.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched